新型免疫治疗时代的T细胞/组织细胞丰富型大B细胞淋巴瘤:聚焦综述
本文聚焦T细胞/组织细胞丰富型大B细胞淋巴瘤(THRLBCL)这一少见侵袭性淋巴瘤,梳理其与结节性淋巴细胞为主型霍奇金淋巴瘤的形态学、免疫表型及分子重叠,总结一线以R-CHOP为标准、疗效与匹配DLBCL相当,以及复发难治阶段无标准治疗、新药数据有限的现状。
要点
- THRLBCL罕见,诊断具挑战性,治疗决策数据匮乏。
- 一线沿用DLBCL的R-CHOP方案,疗效与IPI匹配的DLBCL相当。
- 复发难治阶段无标准治疗,新药证据多来自真实世界数据。
核心结论
- THRLBCL与NLPHL存在形态学、免疫表型及分子重叠,可能处于同一疾病谱系。
- 一线R-CHOP为既定标准治疗,复发难治阶段尚无标准治疗。
研究设计与样本
- 聚焦综述,汇总THRLBCL一线及复发难治治疗数据,重点讨论免疫治疗策略。
主要发现
- THRLBCL罕见,准确诊断具挑战性,治疗决策数据匮乏。
- 一线R-CHOP疗效与IPI匹配的DLBCL相当。
- 复发难治阶段无标准治疗,新药在临床试验中纳入人数少,难以辨别疗效。
- 历史上THRLBCL患者常被排除在临床试验之外,现趋向纳入评估新药的试验。
关键数值与推荐
- 一线标准治疗为利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松(R-CHOP)。
- 复发难治阶段无标准治疗。
临床怎么用
- 一线可参照DLBCL采用R-CHOP方案治疗THRLBCL。
- 复发难治阶段缺乏标准,可考虑临床试验或依赖真实世界数据决策。
局限性
- THRLBCL罕见,临床试验纳入人数少,难以辨别新药疗效。
- 治疗决策数据匮乏,需依赖较大规模真实世界数据集。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is an uncommon aggressive large B-cell lymphoma variant which can develop synchronously or following a diagnosis of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). There is morphological, immunophenotypic and molecular overlap between THRLBCL and NLPHL suggesting that these two entities may lie on the same spectrum. Due to the rarity of THRLBCL, accurate diagnosis can be challenging and there is a paucity of data on which to base treatment decisions. The management has largely followed diffuse large B-cell lymphoma (DLBCL) with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone established as the standard of care in the first line, with outcomes comparable to international prognostic index matched DLBCL. In the relapsed/refractory (R/R) setting, there is no standard of care. There is a move towards inclusion of THRLBCL patients in clinical trials evaluating novel agents, although historically they were commonly excluded. Due to the small numbers included in clinical trials, it has been difficult to discern the effect of novel agents in this cohort. Thus, we are reliant on larger real-world datasets to inform our understanding. This review will examine the data available in the first line and R/R setting with a focus on immunotherapeutic approaches.
引用
- Choy JP, Cheah CY. T-cell/histiocyte-rich large B-cell lymphoma in the era of novel immunotherapy: A focused review. Br J Haematol. 2025. PMID: 41436860. doi:10.1111/bjh.70294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。